Benefits of Bempedoic Acid — Clearer Now
New England Journal of Medicine · 2023
DOI: 10.1056/nejme2301490 ↗Kurz gefasst
Editorial in der Zeitschrift New England Journal of Medicine, 2023. Verfasst von John H Alexander. Beteiligte Einrichtung: From the Division of Cardiology, Duke Clinical Research Institute, Duke Health, Durham, NC. Hauptthemen laut MEDLINE: Hypercholesterolemia, Hypolipidemic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Vascular atherosclerosis begins in young adulthood and progresses over decades. The condition is associated with considerable morbidity and mortality from coronary, cerebrovascular, and peripheral vascular disease. The foundation of contemporary prevention and treatment of atherosclerosis is lowering the serum cholesterol level with 3-hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase inhibitors (statins). Statins reduce the low-density lipoprotein (LDL) cholesterol level, slow the progression of atherosclerosis, and reduce the morbidity and mortality associated with coronary, cerebrovascular, and peripheral vascular events.1 High-intensity statin therapy is recommended for all patients with established atherosclerotic vascular disease, as well as those at high risk for atherosclerotic vascular disease.2 Unfortunately, . . .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Division of Cardiology, Duke Clinical Research Institute, Duke Health, Durham, NC.
Zitieren
APA
Alexander, J. H. (2023). Benefits of Bempedoic Acid — Clearer Now. New England Journal of Medicine. https://doi.org/10.1056/nejme2301490
Vancouver
Alexander JH. Benefits of Bempedoic Acid — Clearer Now. New England Journal of Medicine. 2023. doi:10.1056/nejme2301490
BibTeX
@article{Alexander2023,
author = {Alexander, John H},
title = {Benefits of Bempedoic Acid — Clearer Now},
journal = {New England Journal of Medicine},
year = {2023},
doi = {10.1056/nejme2301490}
}
EUVIMED